NCT05739877

Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State

An Open Label, Randomized, Single Dose, Cross-over ,Two-group Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229\_01(2.5/500 mg x1 tablets) at fed state

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	DA-1229_01 2.5/500mg (Before)	single dose administration (one tablet once a day)
DRUG	DA-1229_01 2.5/500mg (After)	single dose administration (one tablet once a day)

Timeline

• Start date: 2023-03-17
• Primary completion: 2023-04-07
• Completion: 2023-04-07
• First posted: 2023-02-22
• Last updated: 2023-02-22

Locations

1 site across 1 country: South Korea